Synergistic CAR-T Cell Production and Therapy System

A comprehensive system integrating CAR-T cell production, AI-driven quality control, IoT-enabled monitoring, and blockchain-based supply chain management to enhance personalized cancer treatment

The original patent disclosed a method for preparing CAR-T cells with TCM as the main active component, but it had limitations in terms of scalability, quality control, and patient monitoring. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful system

The system comprises a microfluidic device for sorting and isolating TCM cells, a machine learning-based algorithm for optimizing CAR design, and a blockchain-based ledger for tracking CAR-T cell production and distribution. Additionally, the system integrates IoT-enabled biosensors for real-time monitoring of TCM cell activity, AI-driven analytics for predicting and preventing TCM cell exhaustion, and a decentralized blockchain-based supply chain management system for tracking and verifying CAR-T cell products. The system can be further customized using patient genomic data to design personalized CAR-T cell therapy

The new inventive concept introduces a synergistic combination of AI, IoT, blockchain, and microfluidic technologies to enhance CAR-T cell production and therapy, which is not obvious from the original patent. The integration of these distinct technologies provides a new and non-obvious solution for personalized cancer treatment

Alternative embodiments may include using different types of biosensors, varying the machine learning algorithm for CAR design optimization, or implementing different blockchain protocols for supply chain management. Variations may also include integrating additional technologies, such as new materials for CAR-T cell expansion or augmented reality for patient monitoring

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of personalized medicine and immunotherapy. The system's ability to enhance CAR-T cell production and therapy can lead to improved treatment outcomes and reduced costs. Target industries include biotech, pharmaceutical, and healthcare